IDCRC Newsletter: December 2021
Season’s Greetings from the Infectious Diseases
Clinical Research Consortium We want to express our sincere gratitude for all your efforts and dedication this year. Best wishes to you and your family for a joyous and safe holiday season and a happy and healthy new year.
IDCRC Investigator Profile: Martín Bäcker, MD, FAAP
Clinical Assistant Professor, Infectious Diseases & Pediatric Infectious Diseases, NYU Long Island School of Medicine; Clinical Site Lead, NYU VTEU Long Island, Satellite Site, NYU Langone Hospital Long Island Clinical Research Center
"COVID-19 is the perfect example of the raison d'être of IDCRC. The fact that more than one vaccine was authorized in less than a year, from identification of this deadly virus, saving millions of lives, proves the importance of the consortium and how well it has stepped up to the plate when it was needed. It has been a privilege to work with the IDCRC and participate in meetings with not only brilliant individuals with years of experience in vaccinology and infectious diseases, but a level of dedication and commitment second to none.”
Manual of Procedures Sections
View approved IDCRC Manual of Procedures (MOP) sections which describe structure, operating policies, roles and responsibilities of entities and individuals within the unit/consortium:
NOTE: Please include the following citation in any publications resulting from direct or indirect IDCRC support: "Supported by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, under award number UM1AI148684. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."
View recent publication below:
Mentee Profile: Jennifer Whitaker, MD, MS
Assistant Professor of Molecular Virology and Microbiology and Medicine, Infectious Diseases, Baylor College of Medicine
Dr. Whitaker's research focuses on vaccine development through clinical trials. She is interested in assessing vaccine strategies that will lead to improved immunogenicity and efficacy in immunocompromised persons.
View details on current job openings:
Active Studies
Recruiting Volunteers
Gritstone Second Generation COVID-19 Vaccine, CORAL Program
- Moderna’s mRNA-1273 vaccine, the KidCOVE Study
- SARS-CoV-2 Vaccines in Pregnancy and Postpartum, the MOMI-VAX Study
- Heterologous Prime Boost, Mix and Match Study
- Mucosal immunity against GC after 4CMenB Vaccination
Fully Enrolled Studies
in Follow-up
Moderna’s mRNA-1273 vaccine, The COVE Study™
Moderna’s mRNA-1273.351 Variant vaccine
AstraZeneca Study of AZD1222
The ENSEMBLE Study with Janssen’s Ad26.COV2.S Investigational Vaccine
Novavax Study of NVX-CoV2373
Regeneron’s 10933 and 10987 Monoclonal Antibodies, the REGN-COV2 Study
- Eli Lilly’s LY3819253 Antibody, the BLAZE-2 Study
- SARS-CoV-2/COVID-19 PREVALENCE STUDY, The COMPASS Study
IDCRC Concept Quick Stats
NOTE: Protocols Transitioned to IDCRC for Protocol Implementation: 5 Status: Protocol Dev/Pre-implementation: 4; Active Study: 1 Other studies in process (not from an IDCRC concept): 3
Please submit IDCRC news to epthomp@emory.edu for inclusion in the monthly newsletter and IDCRC.org.
|